BCL3 inhibitor JS6   Click here for help

GtoPdb Ligand ID: 12672

Synonyms: compound 1a [WO2015014972]
Compound class: Synthetic organic
Comment: JS6 is a small molecule that was designed to investigate the antimetastatic potential of inhibiting the BCL3 transcription coactivator [1]. Overexpressed BCL3 is an established oncogenic driver in some leukemias and solid tumours. J6S disrupts the interaction of BCL3 with its cognate protein partner NF-κB1 (p50).
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 6
Hydrogen bond donors 2
Rotatable bonds 8
Topological polar surface area 70.67
Molecular weight 371.41
XLogP 0.57
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES C1=CC(=C(C=C1)F)C(=O)NC2=C(C=CC=C2)C(=O)NCCN3CCOCC3
Isomeric SMILES FC1=C(C(=O)NC2=C(C=CC=C2)C(NCCN3CCOCC3)=O)C=CC=C1
InChI InChI=1S/C20H22FN3O3/c21-17-7-3-1-5-15(17)20(26)23-18-8-4-2-6-16(18)19(25)22-9-10-24-11-13-27-14-12-24/h1-8H,9-14H2,(H,22,25)(H,23,26)
InChI Key QEEPXSHOUBCRGQ-UHFFFAOYSA-N
References
1. Soukupová J, Bordoni C, Turnham DJ, Yang WW, Seaton G, Gruca A, French R, Lee KY, Varnava A, Piggott L et al.. (2021)
The Discovery of a Novel Antimetastatic Bcl3 Inhibitor.
Mol Cancer Ther, 20 (5): 775-786. [PMID:33649105]
2. Westwell AD, Brancale A, Clarkson RWE, Soukupova J. (2015)
2-benzoylaminobenzamide derivatives as bcl-3 inhibitors.
Patent number: WO2015014972A1. Assignee: University College Cardiff Consultants Limited. Priority date: 31/07/2014. Publication date: 05/02/2015.